Dengvaxia is a vaccine developed by Sanofi Pasteur specifically to combat the dengue virus. It is the first vaccine approved for the prevention of dengue disease caused by all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Dengue is a mosquito-borne viral infection that can lead to severe flu-like symptoms and, in severe cases, can be fatal.
